Corporate Profile

Affymax, Inc. is a clinical-stage biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematide™, is currently entering Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure and is in Phase 2 clinical trials for the treatment of anemia in cancer patients.

Webcasts

May 21, 2008
2008 Citi Investment Research Global Health Care Conference

Recent Press Releases

May 9, 2008
Affymax(R) Reports First Quarter 2008 Financial Results

Apr 22, 2008
Affymax Announces Upcoming Webcasts and Conference Participation